path(MESH:Vomiting) association a(MESH:"5-(2-azetidinylmethoxy)-2-chloropyridine")

PubMed:19721446

The first nicotinic receptor ligand to undergo Phase ii clinical trials for analgesic activity was the potent Abbott compound ABT-594, a nAChR agonist that preferentially targets α4β2 (ReFS 231–235). The compound allowed for the clinical proof of concept, but could not be developed further because of adverse effects such as emesis and nausea236. As these adverse effects seemed to be attributable to the activation of the ganglionic α3β4 nAChR receptors, Abbott undertook a search for more selective α4β2 agonists, independently and in cooperation with Neurosearch.

Related Edges 5

• a(MESH:"5-(2-azetidinylmethoxy)-2-chloropyridine") increases act(p(HBP:"alpha-4 beta-2 nAChR"))
• a(MESH:"5-(2-azetidinylmethoxy)-2-chloropyridine") association path(MESH:Vomiting)
• a(MESH:"5-(2-azetidinylmethoxy)-2-chloropyridine") association path(MESH:Nausea)
• a(MESH:"5-(2-azetidinylmethoxy)-2-chloropyridine") increases act(complex(p(HGNC:CHRNA3), p(HGNC:CHRNB4)))
• path(MESH:Nausea) association a(MESH:"5-(2-azetidinylmethoxy)-2-chloropyridine")

Text Location

Review

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.